Compare NFGC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NFGC | ACRS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.5M | 608.9M |
| IPO Year | 2021 | 2015 |
| Metric | NFGC | ACRS |
|---|---|---|
| Price | $1.50 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $3,542.00 | N/A |
| Revenue Next Year | $118.57 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $1.46 |
| 52 Week High | $3.59 | $5.85 |
| Indicator | NFGC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 65.27 |
| Support Level | $1.45 | $4.13 |
| Resistance Level | $2.12 | N/A |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 18.64 | 77.41 |
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.